Clinic Roundup
Synergy Pharmaceuticals Inc., of New York, completed a Phase I single-ascending dose trial of SP-333 for ulcerative colitis and other gastrointestinal diseases. The placebo-controlled, dose-escalating trial assessed safety and pharmacodynamics in eight volunteer cohorts, dosed from 0.1 mg to 60 mg.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.